Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $20.04M (cash outflow) fell 64.3% year over year, behind the -48.4% change in trailing-twelve-month net income. Sequentially, it fell 15.0% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$87.57M (-41.4%) for the fiscal year ending Dec 2026, a slowdown from the -29.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.04M-15.0% QoQ
- Last fiscal yearDec 2025
- -$149.34M-29.0% YoY
- LTMMar 2026
- -$113.22M-48.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -64.3% | -51.1% | +13.2 pp |
| 1 year | -29.0% | -41.4% | -12.4 pp |
| 3-year CAGR | +6.6% | -23.9% | -30.5 pp |
| 5-year CAGR | -40.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (149.34M) USD
- Year-over-year change
- +29.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (149.34M) | +29.0% |
| FY2024 | 2024-12-31 | (210.3M) | -30.4% |
| FY2023 | 2023-12-31 | (161.34M) | -30.8% |
| FY2022 | 2022-12-31 | (123.32M) | -26.8% |
| FY2021 | 2021-12-31 | (97.26M) | — |
Net Income vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 net income of $113.22M is the 3rd largest of the 10 companies compared; the peer median is $70.36M.
- Its year-over-year change of -48.4% is the 9th highest of 10, against a peer median of +15.3%.
- Over three fiscal years its annual growth of +6.6% compares with a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $124.13M | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $108M | +21.2% | +44.8% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M | +21.4% | +12.6% | — |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $33.51M | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $24.17M | -3.2% | -31.5% | 339.3% | |
| LTM Mar 2026 | $21.13M | +23.3% | +20.1% | 266.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M | -67.7% | -30.2% | 288.3% |
| Peer median (excluding PLRX) | $70.36M | +15.3% | -4.4% | 277.2% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Depreciation & Amortization | 1.54M | 1.82M | 1.84M | 2.13M | 1.7M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.44M | 22.6M | 44.48M | 37.63M | 26.23M |
| Change in Working Capital | 6.92M | 4.22M | 1.25M | 9.09M | (15.94M) |
| Accounts Receivables | 7.28M | 15K | 1.98M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 891K | (1.35M) | 2.97M | 1.43M | (5.48M) |
| Other Working Capital | (1.26M) | 5.55M | (3.7M) | 7.66M | (10.46M) |
| Other Non-Cash Items | 2.93M | 52K | (2.6M) | 5.96M | 9.02M |
| Operating Cash Flow | (75.44M) | (94.63M) | (116.36M) | (155.5M) | (128.34M) |
| Capital Expenditures | (1.95M) | (1.76M) | (921K) | (3.85M) | (374K) |
| Acquisitions (Net) | (75.65M) | 148.44M | 0 | 0 | 155K |
| Purchases of Investments | (219.89M) | (325.72M) | (583.07M) | (211.29M) | (203.4M) |
| Sales of Investments | 295.54M | 177.27M | 456.98M | 355.47M | 337.91M |
| Other Investing Activities | 75.65M | (148.44M) | 0 | 0 | 0 |
| Investing Cash Flow | 73.7M | (150.2M) | (127.01M) | 140.34M | 134.29M |
| Debt Repayment | 0 | 10M | 0 | 19.91M | (32.27M) |
| Common Stock Issued | 2.98M | 215.64M | 275.25M | 3.21M | 570K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (457K) | 1.21M | 5M | 0 | 0 |
| Financing Cash Flow | 2.53M | 226.85M | 274.41M | 23.12M | (31.7M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 783K | (17.98M) | 31.03M | 7.95M | (25.74M) |
| Free Cash Flow | (77.4M) | (96.39M) | (117.28M) | (159.35M) | (128.71M) |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.